MUC16 and ovarian cancer: Additionally, multiplexed magnetic nanoparticle-antibody conjugates combining MUC16, B2M, and APOA1 achieved high sensitivity (94%) and specificity (98%) in distinguishing early-stage ovarian cancer patients from healthy individuals (Pal et al., 2015).